Novartis India Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Novartis India Ltd is ₹ 1050 as of 06 May 15:30 . The P/E Ratio of Novartis India Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Novartis India Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The revenue of Novartis India Ltd for the Dec '25 is ₹ 94.65 crore as compare to the Sep '25 revenue of ₹ 99.73 crore. This represent the decline of -5.09% The revenue of Sai Parenterals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 31.11 crore as compare to the Sep '25 ebitda of ₹ 33.28 crore. This represent the decline of -6.52% The ebitda of Sai Parenterals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 16.09 crore over 7 quarters. This represents a CAGR of -23.55% The net profit of Sai Parenterals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Novartis India Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Novartis India Ltd or Sai Parenterals Ltd?

Market cap of Novartis India Ltd is 2,563 Cr while Market cap of Sai Parenterals Ltd is 2,161 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Sai Parenterals Ltd?

The stock performance of Novartis India Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Sai Parenterals Ltd?

As of May 6, 2026, the Novartis India Ltd stock price is INR ₹1038.1. On the other hand, Sai Parenterals Ltd stock price is INR ₹489.35.

How do dividend payouts of Novartis India Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.